Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Boucher, 2017, White paper: developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs, J Infect Dis, 216, 228, 10.1093/infdis/jix211
2017
Gutiérrez-Gutiérrez, 2017, European prospective cohort study on enterobacteriaceae showing resistance to carbapenems (EURECA): a protocol of a European multicentre observational study, BMJ Open, 7, 10.1136/bmjopen-2016-015365
Doi, 2019, Treatment options for carbapenem-resistant Gram-negative bacterial infections, Clin Infect Dis, 69, S565, 10.1093/cid/ciz830
Paterson, 2020, New treatment options for multiresistant Gram negatives, Curr Opin Infect Dis, 33, 214, 10.1097/QCO.0000000000000627
Ito, 2016, In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria, J Antimicrob Chemother, 71, 670, 10.1093/jac/dkv402
Ito, 2017, In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria, Antimicrob Agents Chemother, 62, e01454
Ito-Horiyama, 2016, Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases, Antimicrob Agents Chemother, 60, 4384, 10.1128/AAC.03098-15
Ito, 2018, Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae, J Antimicrob Chemother, 73, 3049, 10.1093/jac/dky317
Sato, 2019, Cefiderocol: discovery, chemistry, and pharmacological profiles of a novel siderophore cephalosporin, Clin Infect Dis, 69, S538, 10.1093/cid/ciz826
Hackel, 2017, In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study), Antimicrob Agents Chemother, 61, e00093, 10.1128/AAC.00093-17
Karlowsky, 2019, In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015, Int J Antimicrob Agents, 53, 456, 10.1016/j.ijantimicag.2018.11.007
Katsube, 2019, Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin, Clin Infect Dis, 69, S552, 10.1093/cid/ciz828
Echols, 2019, Pathogen-focused clinical development to address unmet medical need: cefiderocol targeting carbapenem resistance, Clin Infect Dis, 69, S559, 10.1093/cid/ciz829
Portsmouth, 2018, Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial, Lancet Infect Dis, 18, 1319, 10.1016/S1473-3099(18)30554-1
Wunderink, 2020, Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial, Lancet Infect Dis
Bassetti, 2019, Designing a pathogen-focused study to address the high unmet medical need represented by carbapenem-resistant Gram-negative pathogens—the international, multicenter, randomized, open-label, phase 3 CREDIBLE-CR study, Infect Drug Resist, 12, 3607, 10.2147/IDR.S225553
Wunderink, 2018, Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial, Infect Dis Ther, 7, 439, 10.1007/s40121-018-0214-1
McKinnell, 2019, Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae, N Engl J Med, 380, 791, 10.1056/NEJMc1807634
Motsch, 2020, RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing the efficacy and safety of imipenem/relebactam versus colistin plus imipenem in patients with imipenem-non-susceptible bacterial infections, Clin Infect Dis, 70, 1799, 10.1093/cid/ciz530
Mehta, 2018, Beware of broad-spectrum generalizations: ceftazidime-avibactam compared to meropenem for the treatment of gram-negative pneumonia, J Emerg Crit Care Med, 2, 45, 10.21037/jeccm.2018.05.02
2020
2020
Paul, 2018, Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial, Lancet Infect Dis, 18, 391, 10.1016/S1473-3099(18)30099-9
Kadri, 2019, Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithms, Am J Infect Control, 47, 1040, 10.1016/j.ajic.2019.01.010
Durante-Mangoni, 2013, Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial, Clin Infect Dis, 57, 349, 10.1093/cid/cit253
Sirijatuphat, 2014, Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections, Antimicrob Agents Chemother, 58, 5598, 10.1128/AAC.02435-13
Lodise TP, Bassetti M, Ferrer Roca R, et al. Comparison of 28-day mortality rates of recently completed prospective, randomised treatment studies of adult patients with carbapenem-resistant Gram-negative bacterial infections (CR-GNBIs). 30th European Congress of Clinical Microbiology and Infectious Diseases; Paris, France; April 18–21, 2020 (abstr 2497).
Leão, 2016, Acinetobacter spp are associated with a higher mortality in intensive care patients with bacteremia: a survival analysis, BMC Infect Dis, 16, 386, 10.1186/s12879-016-1695-8
Garnacho-Montero, 2019, Managing Acinetobacter baumannii infections, Curr Opin Infect Dis, 32, 69, 10.1097/QCO.0000000000000518